🚀 VC round data is live in beta, check it out!
Biogened Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biogened and similar public comparables like Abera Bioscience, Jupiter Neurosciences, NFL Biosciences, NextCell Pharma and more.
Biogened Overview
About Biogened
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
Founded
2007
HQ
Employees
227
Website
Sectors
Financials (FY)
EV
$20M
Biogened Financials
Biogened reported last fiscal year revenue of $32M and EBITDA of $4M.
In the same fiscal year, Biogened generated $20M in gross profit, $4M in EBITDA, and $1M in net income.
Biogened P&L
In the most recent fiscal year, Biogened reported revenue of $32M and EBITDA of $4M.
Biogened expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $32M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $20M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 64% | XXX | XXX | XXX |
| EBITDA | — | XXX | $4M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 12% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 8% | XXX | XXX | XXX |
| Net Profit | — | XXX | $1M | XXX | XXX | XXX |
| Net Margin | — | XXX | 4% | XXX | XXX | XXX |
| Net Debt | — | — | $4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biogened Stock Performance
Biogened has current market cap of $16M, and enterprise value of $20M.
Market Cap Evolution
Biogened's stock price is $6.35.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20M | $16M | 0.1% | XXX | XXX | XXX | $0.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiogened Valuation Multiples
Biogened trades at 0.6x EV/Revenue multiple, and 5.4x EV/EBITDA.
Biogened Financial Valuation Multiples
As of April 19, 2026, Biogened has market cap of $16M and EV of $20M.
Equity research analysts estimate Biogened's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biogened has a P/E ratio of 12.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16M | XXX | $16M | XXX | XXX | XXX |
| EV (current) | $20M | XXX | $20M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 8.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1.0x | XXX | XXX | XXX |
| P/E | — | XXX | 12.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 14.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biogened Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biogened Margins & Growth Rates
Biogened's revenue in the last fiscal year grew by 3%.
Biogened's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Biogened Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 1% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 43% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biogened Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Biogened | XXX | XXX | XXX | XXX | XXX | XXX |
| Abera Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Jupiter Neurosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| NFL Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| NextCell Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Genenta Science | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biogened M&A Activity
Biogened acquired XXX companies to date.
Last acquisition by Biogened was on XXXXXXXX, XXXXX. Biogened acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biogened
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiogened Investment Activity
Biogened invested in XXX companies to date.
Biogened made its latest investment on XXXXXXXX, XXXXX. Biogened invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biogened
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biogened
| When was Biogened founded? | Biogened was founded in 2007. |
| Where is Biogened headquartered? | Biogened is headquartered in Poland. |
| How many employees does Biogened have? | As of today, Biogened has over 227 employees. |
| Is Biogened publicly listed? | Yes, Biogened is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Biogened? | Biogened trades under BGD ticker. |
| When did Biogened go public? | Biogened went public in 2011. |
| Who are competitors of Biogened? | Biogened main competitors are Abera Bioscience, Jupiter Neurosciences, NFL Biosciences, NextCell Pharma. |
| What is the current market cap of Biogened? | Biogened's current market cap is $16M. |
| What is the current revenue of Biogened? | Biogened's last fiscal year revenue is $32M. |
| What is the current EV/Revenue multiple of Biogened? | Current revenue multiple of Biogened is 0.6x. |
| Is Biogened profitable? | No, Biogened is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.